Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Market Experts Bullish on MSCI Ahead of Earnings Report

Felix Baarz by Felix Baarz
January 15, 2026
in Analysis, Earnings, S&P 500
0
Msci Stock
0
SHARES
14
VIEWS
Share on FacebookShare on Twitter

A series of price target upgrades in mid-January has bolstered confidence in the financial data provider MSCI. Market strategists point to accelerating subscription growth, underpinned by the firm’s resilient recurring revenue model. The upcoming quarterly results will be a key test for this optimistic sentiment.

Key Data Points:
* Recent Share Price: The stock closed at $594.79 in the last session, marking a gain of 1.25%.
* Upcoming Report: MSCI is scheduled to release its Q4 and full-year 2025 financial figures before the market opens on Wednesday, January 28. A conference call for investors is set for 11:00 a.m. Eastern Time.
* Earnings Forecast: The consensus estimate for quarterly earnings per share (EPS) stands at $4.59.
* Analyst Price Target: The average 12-month price target among covering analysts is $650.13.
* One-Year Performance: Over the past twelve months, the share price has declined by 1.96%.

A Wave of Upgraded Forecasts

The positive shift in analyst outlook is evidenced by several specific actions. On January 13, Raymond James increased its target price to $690 from $680, reaffirming its “Outperform” rating on the equity. The following day, Wells Fargo raised its target to $590, up from $570, while maintaining an “Equalweight” stance. This adjustment suggests an improved view of the company’s fundamentals without a change in the overall recommendation.

Should investors sell immediately? Or is it worth buying Msci?

Supporting this view, RBC Capital Markets highlighted in mid-January that MSCI is demonstrating building momentum in its subscription business. The firm sees this as creating a solid foundation for future recurring income streams. Collectively, these revisions indicate a broad-based reassessment of the company’s growth trajectory, with multiple researchers anticipating a medium-term reacceleration of subscription growth into double-digit percentages.

All Eyes on the January 28 Earnings Release

The immediate focus for investors is squarely on the fourth-quarter report due at the end of January. The consensus EPS expectation of $4.59 will serve as a benchmark. More critically, the market will scrutinize whether the reported figures reflect the anticipated subscription momentum and what guidance management provides for the coming periods.

Should the results meet or exceed expectations and confirm an acceleration in subscription growth, the current optimistic analyst stance and elevated price targets are likely to be validated. Conversely, if the earnings disappoint or MSCI reports weaker subscriber metrics, a downward revision of targets and a recalibration of growth expectations would be a probable outcome. The report will ultimately determine if the recent analyst confidence is well-founded.

Ad

Msci Stock: Buy or Sell?! New Msci Analysis from February 7 delivers the answer:

The latest Msci figures speak for themselves: Urgent action needed for Msci investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Msci: Buy or sell? Read more here...

Tags: MSCI
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Next Post
Deere Stock

Diverging Views Emerge on Deere's Stock Trajectory

Cassava Sciences Stock

Cassava Sciences Faces Critical Juncture After Alzheimer's Trial Failure

Apex Critical Metals Stock

Major Shareholder Deepens Stake in Apex Critical Metals

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com